- Home
- NCZ vs FDMT Comparison
NCZ vs FDMT Comparison
Compare NCZ & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- FDMT
- Stock Information
- Founded
- NCZ 2003
- FDMT 2013
- Country
- NCZ United States
- FDMT United States
- Employees
- NCZ N/A
- FDMT N/A
- Industry
- NCZ Finance Companies
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- FDMT Health Care
- Exchange
- NCZ Nasdaq
- FDMT Nasdaq
- Market Cap
- NCZ 240.5M
- FDMT 268.6M
- IPO Year
- NCZ N/A
- FDMT 2020
- Fundamental
- Price
- NCZ $3.21
- FDMT $4.58
- Analyst Decision
- NCZ
- FDMT Buy
- Analyst Count
- NCZ 0
- FDMT 11
- Target Price
- NCZ N/A
- FDMT $41.70
- AVG Volume (30 Days)
- NCZ 533.0K
- FDMT 1.1M
- Earning Date
- NCZ 01-01-0001
- FDMT 02-27-2025
- Dividend Yield
- NCZ 12.16%
- FDMT N/A
- EPS Growth
- NCZ N/A
- FDMT N/A
- EPS
- NCZ N/A
- FDMT N/A
- Revenue
- NCZ N/A
- FDMT $17,000.00
- Revenue This Year
- NCZ N/A
- FDMT N/A
- Revenue Next Year
- NCZ N/A
- FDMT $159.49
- P/E Ratio
- NCZ N/A
- FDMT N/A
- Revenue Growth
- NCZ N/A
- FDMT N/A
- 52 Week Low
- NCZ $2.50
- FDMT $4.50
- 52 Week High
- NCZ $3.15
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- NCZ 54.17
- FDMT 30.88
- Support Level
- NCZ $3.06
- FDMT $4.68
- Resistance Level
- NCZ $3.22
- FDMT $5.15
- Average True Range (ATR)
- NCZ 0.06
- FDMT 0.43
- MACD
- NCZ 0.01
- FDMT -0.05
- Stochastic Oscillator
- NCZ 78.95
- FDMT 3.69
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas and consumable fuels and others.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.